Sight Sciences (SGHT) Cash & Equivalents (2020 - 2026)

Sight Sciences' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $85.0 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 21.89% year-over-year to $85.0 million in Q1 2026; TTM through Mar 2026 was $85.0 million, a 21.89% decrease from a year earlier, with the FY2025 full-year figure at $92.0 million, down 23.59% from the prior year.
• Cash & Equivalents declined to $85.0 million in Q1 2026 per SGHT's latest filing, from $92.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $238.6 million in Q1 2022 and bottomed at $85.0 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $127.3 million (2024), against an average of $141.9 million.
• Across the five-year window, Cash & Equivalents jumped 518.74% in 2022 and fell 29.86% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $185.0 million in 2022, then slipped by 25.34% to $138.1 million in 2023, then slipped by 12.87% to $120.4 million in 2024, then fell by 23.59% to $92.0 million in 2025, then slipped by 7.61% to $85.0 million in 2026.
• Per Business Quant, the three latest SGHT Cash & Equivalents figures stand at $85.0 million (Q1 2026), $92.0 million (Q4 2025), and $92.4 million (Q3 2025).